PsyMuKB

PPI network (data source: BioGrid)

A gene is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the mean normalized expression(base 2 log of (TPM+1)) +1 in all brain tissue from GTEx v7 or BrainSpan data.

A protein is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the normalized expression (base 10 log of iBAQ intensity) ≥0.5 in at least one brain tissue from ProteomicsDB data. Otherwise, a gene or protein is determined as either with below-cutoff expressions or no available data.

	The queried gene/protein
	The interacting partner is expressed at mRNA-level
	The interacting partner is expressed at protein-level
	The interacting partner is expressed at both mRNA and protein level
	The interacting partner is with either below-cutoff expressions or no expression data at both mRNA and protein level
	The interacting partner is hit by coding DNMs
	Physical interaction between queried gene/protein and its partner
	Physical interaction between two interacting partners

Symbol A	GeneA coding DNM count	Symbol B	GeneB coding DNM count	Interaction detection method	Publication	Evidence
CELA2B	1	UBE3A	4	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
CELA2B	1	AURKA	1	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
CELA2B	1	C16orf70	4	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
CELA2B	1	GRN	2	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
CELA2B	1	STXBP3	3	affinity chromatography technology	Huttlin EL (2015)	1
CELA2B	1	MRE11	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
CELA2B	1	RAD50	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
NBN	1	RAD50	3	biochemical, affinity chromatography technology, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, biochemical, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Wang Y (2000), Cerosaletti KM (2003), Trujillo KM (1998), Desai-Mehta A (2001), Goldberg M (2003), Goldberg M (2003), Cho YW (2007), Nakanishi K (2002), Greenberg RA (2006), Falck J (2005), Wu J (2012), Alt JR (2005), Havugimana PC (2012), Wan C (2015), Suhasini AN (2013), Suhasini AN (2013), Lee KY (2015)	17
CELA2B	1	KRT40	0	two hybrid	Rolland T (2014)	1
CELA2B	1	COL4A2	2	affinity chromatography technology	Huttlin EL (2015)	1
CELA2B	1	RPUSD2	1	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
TP53	0	UBE3A	4	pull down, pull down, affinity chromatography technology, enzymatic study, enzymatic study, pull down, enzymatic study, pull down, affinity chromatography technology, pull down, enzymatic study, pull down, enzymatic study, enzymatic study, affinity chromatography technology, x-ray crystallography, enzymatic study	Nuber U (1998), Huibregtse JM (1993), Yang Y (2007), Kim HC (2009), Scheffner M (1994), Mishra A (2012), Burch L (2004), Ro HS (2006), Nakagawa S (2000), Nakagawa S (2000), Nakagawa S (2000), Huibregtse JM (1991), Honda R (1997), Huibregtse JM (1995), Martinez-Zapien D (2016), Martinez-Zapien D (2016), Rolfe M (1995)	17
CELA2B	1	MRM2	1	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
MRE11	3	RAD50	3	biochemical, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, biochemical, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Wang Y (2000), Chiba N (2001), Chiba N (2001), Chiba N (2001), Dolganov GM (1996), Dolganov GM (1996), Trujillo KM (1998), Goedecke W (1999), Zheng L (2009), Goldberg M (2003), Goldberg M (2003), Goldberg M (2003), Cho YW (2007), Cho YW (2007), Greenberg RA (2006), Alt JR (2005), Alt JR (2005), Havugimana PC (2012), Wan C (2015), Wijnhoven P (2015), Boldt K (2016), Suhasini AN (2013), Suhasini AN (2013), Lee KY (2015), Nicholson J (2017)	25
CELA2B	1	TP53	0	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
NBN	1	MRE11	3	biochemical, affinity chromatography technology, biochemical, two hybrid, two hybrid, affinity chromatography technology, imaging technique, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, pull down, imaging technique, affinity chromatography technology, affinity chromatography technology, biochemical, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Wang Y (2000), Cerosaletti KM (2003), Trujillo KM (1998), Matsuzaki K (2008), Desai-Mehta A (2001), Desai-Mehta A (2001), Desai-Mehta A (2001), Zheng L (2009), Goldberg M (2003), Goldberg M (2003), Goldberg M (2003), Cho YW (2007), Nakanishi K (2002), Shimada M (2009), Shimada M (2009), Yanagihara H (2011), Falck J (2005), Falck J (2005), Falck J (2005), Wu J (2012), Alt JR (2005), Havugimana PC (2012), Wijnhoven P (2015), Suhasini AN (2013), Suhasini AN (2013), Nicholson J (2017)	26
CELA2B	1	NBN	1	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
TP53	0	AURKA	1	two hybrid, affinity chromatography technology, affinity chromatography technology, pull down, genetic interference, pull down, pull down, affinity chromatography technology, affinity chromatography technology, enzymatic study, affinity chromatography technology, affinity chromatography technology	Chen SS (2002), Chen SS (2002), Chen SS (2002), Chen SS (2002), Chen SS (2002), Katayama H (2004), Katayama H (2004), Katayama H (2004), Katayama H (2004), Hsueh KW (2013), Huttlin EL (2015), Huttlin EL (2017)	12
CELA2B	1	ATXN2	3	affinity chromatography technology, affinity chromatography technology	Huttlin EL (2015), Huttlin EL (2017)	2
CELA2B	1	CD109	2	affinity chromatography technology	Huttlin EL (2015)	1